Ionis Pharmaceuticals
IONS
325 hedge funds and large institutions have $4.08B invested in Ionis Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 108 increasing their positions, 102 reducing their positions, and 47 closing their positions.
23% more call options, than puts
Call options by funds: $34.5M | Put options by funds: $28M
6% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 102
2.02% less ownership
Funds ownership: 88.26% → 86.24% (-2%)
4% less funds holding
Funds holding: 338 → 325 (-13)
18% less capital invested
Capital invested by funds: $4.96B → $4.08B (-$878M)
21% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 47
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$47.6M |
| 2 |
ClearBridge Investments
New York
|
+$19.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$18.8M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.5M |
| 3 |
Renaissance Technologies
New York
|
-$25.6M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$21.9M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$21M |
IONS Hedge Fund Activity: Q3 2021 in Review
325 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2021, worth a combined $4.08B — down 18% from $4.96B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of IONS and 37 opened new positions — a net loss of 10 holders — while 102 trimmed existing stakes and 108 added.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $47.6M. The largest seller was Vanguard Group, cutting an estimated $32.2M.
- 325 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2021, down from 338 in Q2 2021.
- Funds reported $4.08B of Ionis Pharmaceuticals stock for Q3 2021, down 18% quarter-over-quarter.
- 37 funds opened new Ionis Pharmaceuticals positions in Q3 2021 and 47 closed out, a net change of -10 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2021 was Thrivent Financial for Lutherans, an estimated $47.6M added.
- The largest Ionis Pharmaceuticals seller in Q3 2021 was Vanguard Group, an estimated $32.2M sold.
Based on aggregated 13F filings for Q3 2021.